In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...

We came across a bullish thesis on Regeneron Pharmaceuticals, Inc. (REGN) on Notes From The Beauty Contest’s Substack. In ...

Much of this decline can be attributed to the company’s weaker-than-expected performance, particularly concerning its existing blockbuster treatment, Eylea. Adding to Regeneron’s woes ...

Regeneron Pharmaceuticals, Inc. REGN is looking to make inroads in the lucrative obesity market. The company recently entered ...

Regeneron (REGN) performed poorly. REGN stock entered a prolonged downtrend, despite no major news that would explain the decline. Last Friday, May 30, Regeneron and its drug development partner ...

Regeneron reported Eylea sales of $4.7 billion in the first six months of the year - a decline of 4%, with $2.9 billion from that total coming from the US market. Sales of Vabysmo, meanwhile ...

The company said this morning that the COAST trial of sozinibercept (OPT-302) as a combination therapy with blockbuster wet AMD therapy Regeneron/Bayer's Eylea (aflibercept) wasn't able to show ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection. In March 23andMe said that ...